Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis

References

• Azuaga AB, Ramírez J, Cañete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901. doi: 10.3390/ijms24054901
   PubMed Web of Science ®Google Scholar
• Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314–J21. doi: 10.1016/j.jaut.2009.12.001
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65.e19. doi: 10.1016/j.jaad.2018.06.027
   PubMed Web of Science ®Google Scholar
• Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(5):405–417. doi: 10.1080/1744666X.2018.1468252
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: a cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020;6(1):e001223. doi: 10.1136/rmdopen-2020-001223
   PubMed Web of Science ®Google Scholar
• Hutton J, Mease P, Jadon D. Horizon scan: state-of-the-art therapeutics for psoriatic arthritis. Best Pract Res Clin Rheumatol. 2022;36(4):101809. doi: 10.1016/j.berh.2022.101809
   PubMed Web of Science ®Google Scholar
• Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38–48. doi: 10.1016/S0140-6736(22)02303-0
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi: 10.1007/s12016-018-8702-3
   PubMed Web of Science ®Google Scholar
• Nie YJ, Wu SH, Xuan YH, et al. Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis. Mil Med Res. 2022;9(1):21. doi: 10.1186/s40779-022-00382-3
   PubMed Web of Science ®Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–532. doi: 10.1136/annrheumdis-2017-212127
   PubMed Web of Science ®Google Scholar
• McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25–37. doi: 10.1016/S0140-6736(22)02302-9
   PubMed Web of Science ®Google Scholar
• Ali Z, Matthews R, Al-Janabi A, et al. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2021;17(10):1073–1081. doi: 10.1080/1744666X.2021.1967748
   PubMed Web of Science ®Google Scholar
• Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. doi: 10.3389/fimmu.2020.01894
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):142–152. doi: 10.1056/NEJMoa2102383
   PubMed Web of Science ®Google Scholar
• Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of Brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Investig. 2017;37(5):439–451. doi: 10.1007/s40261-017-0500-9
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427–440. doi: 10.1016/S0140-6736(19)33161-7
   PubMed Web of Science ®Google Scholar
• Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016;13(10):1461–1473. doi: 10.1080/17425247.2016.1188801
   PubMed Web of Science ®Google Scholar
• Boutet MA, Nerviani A, Gallo Afflitto G, et al. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530. doi: 10.3390/ijms19020530
   PubMed Web of Science ®Google Scholar
• Vecellio M, Hake VX, Davidson C, et al. The IL-17/IL-23 axis and its genetic contribution to psoriatic arthritis. Front Immunol. 2020;11:596086. doi: 10.3389/fimmu.2020.596086
   PubMed Web of Science ®Google Scholar
• Blair HA. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2021;81(4):483–494. doi: 10.1007/s40265-021-01476-3
   PubMed Web of Science ®Google Scholar
• Bolt JW, van Kuijk AW, Teunissen MBM, et al. Impact of adalimumab treatment on Interleukin-17 and Interleukin-17 receptor expression in skin and synovium of psoriatic arthritis patients with mild psoriasis. Biomed. 2022;10(2):324. doi: 10.3390/biomedicines10020324
   Google Scholar
• Mahmoud AM. Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients. Curr Med Res Opin. 2023;39(7):1031–1043. doi: 10.1080/03007995.2023.2228613
   PubMed Web of Science ®Google Scholar
• Freitas E, Blauvelt A, Torres T. Bimekizumab for the treatment of psoriasis. Drugs. 2021;81(15):1751–1762. doi: 10.1007/s40265-021-01612-z
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019;71(7):1112–1124. doi: 10.1002/art.40851
   PubMed Web of Science ®Google Scholar
• Eder L, Tony HP, Odhav S, et al. Responses to Ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials. Rheumatol Ther. 2022;9(3):919–933. doi: 10.1007/s40744-022-00445-w
   PubMed Web of Science ®Google Scholar
• Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382(9887):158–169. doi: 10.1016/S0140-6736(13)60439-0
   PubMed Web of Science ®Google Scholar
• Pandey A, Khan MS, Patel KV, et al. Predicting and preventing heart failure in type 2 diabetes. Lancet Diabetes Endocrinol. 2023;11(8):607–624. doi: 10.1016/S2213-8587(23)00128-6
   PubMed Web of Science ®Google Scholar
• Bakhsh W, Nicandri G. Anatomy and physical examination of the shoulder. Sports Med Arthrosc Rev. 2018;26(3):e10–e22. doi: 10.1097/JSA.0000000000000202
   PubMed Web of Science ®Google Scholar
• Nawata M, Someya K, Aritomi T, et al. Subclinical synovitis detected by magnetic resonance imaging and ultrasonography following clinical remission in patients with rheumatoid arthritis: a retrospective study. Rheumatol Autoimmunity. 2021;1(1):9–17. doi: 10.1002/rai2.12006
   Google Scholar
• Loft ND, Vaengebjerg S, Halling AS, et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2020;34(6):1151–1160. doi: 10.1111/jdv.16073
   PubMed Web of Science ®Google Scholar